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Abstract  17 
In all animals, the transition between night and day engages a host of physiological and 18 
behavioural rhythms. These rhythms depend not on the rods and cones of the retina, 19 
but on retinal ganglion cells (RGCs) that detect the ambient light level in the 20 
environment. These project to the suprachiasmatic nucleus (SCN) of the hypothalamus 21 
to entrain circadian rhythms that are generated within the SCN. The neuropeptide 22 
vasopressin has an important role in this entrainment. Many SCN neurons express 23 
vasopressin, and it has been assumed that the role of vasopressin in the SCN reflects the 24 
activity of these cells. Here we show that vasopressin is also expressed in many retinal 25 
cells that project to the SCN. Light-evoked vasopressin release contributes to the 26 
responses of SCN neurons to light, and enhances expression of the immediate early gene 27 
c-fos in the SCN, which is involved in photic entrainment of circadian rhythms. 28 
 29 
Key points  30 
• A subpopulation of retinal ganglion cells expresses the neuropeptide vasopressin  31 
• These retinal ganglion cells project predominately to our biological clock, the SCN 32 
• Light-induced vasopressin release enhances the responses of SCN neurons to light. 33 
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• It also enhances expression of genes involved in photo-entrainment of biological 34 
rhythms 35 
 36 
Abbreviations: BSA, bovine serum albumin; CSF, cerebrospinal fluid; DABCO, 1,4-37 
diazabicyclo[2.2.2]octane; DAPI, 4',6-diamidino-2-phenylindole; eGFP, enhanced green 38 
fluorescent protein RGCs; retinal ganglion cells; GRP, gastrin-releasing peptide; IGL, 39 
intergeniculate leaflet; Opt, olivary pretectal nucleus; PFA, paraformaldehyde; RIA, 40 
radioimmunoassay; rAVV, recombinant adeno-associated virus; RHT, retino-hypothalamic 41 
tract; SCN, suprachiasmatic nucleus; VP-RGCs, vasopressin-expressing retinal ganglion 42 
cells; V1a, vasopressin receptor antagonist (d(CH2)5Tyr(Me)2AVP; vGLUT-2, vesicle 43 
glutamate transporter 2; VIP, vasoactive intestinal polypeptide; ZT, Zeitgeber time;  44 
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Introduction 67 
The suprachiasmatic nucleus (SCN) of the hypothalamus is the circadian pacemaker 68 
of the mammalian brain, orchestrating diurnal cycles in activity, hormone secretion and other 69 
physiological variables (Reppert & Weaver, 2002; Hastings et al., 2003; Froy, 2011; 70 
Albrecht, 2012) according to an intrinsic circadian rhythmicity of neuronal activity and gene 71 
expression. Light entrains the endogenous oscillator in the SCN, synchronizing it with the 72 
day-night cycle (Golombek & Rosenstein, 2010), and in mammals information about ambient 73 
light intensity originates from a small subset of retinal ganglion cells (RGCs) that are 74 
intrinsically photosensitive (Masland, 2001; Hattar et al., 2002; Schmidt et al., 2011), rather 75 
than from the rods and cones that are responsible for visual imaging. These intrinsically 76 
photosensitive RGCs express the photopigment melanopsin (Lucas, 2013), and use the 77 
neurotransmitter glutamate (Marc & Jones, 2002); they project to the SCN to mediate 78 
circadian photoentrainment. This neural circuit is independent of conventional retinal 79 
phototransduction, since photic entrainment persists in functionally blind transgenic mice 80 
lacking rods and cones (Berson et al., 2002). 81 
Changes in day length require progressive adjustments of circadian rhythms, but it 82 
would be counter-adaptive to reset a rhythm to any unexpected light signal. Our experience 83 
of jet-lag reflects the resistance of our bodily rhythms to abrupt changes (LeGates et al., 84 
2014). Accordingly, in animals, a flash of light close to the end of the night is more likely to 85 
result in a phase shift of circadian rhythms than one given earlier. Such light pulses induce 86 
expression of a set of immediate-early genes in the SCN, and the ability of light to re-entrain 87 
circadian rhythms correlates well with the induction of these genes (Rusak et al., 1993; 88 
Kornhauser et al., 1996; Porterfield & Mintz, 2009). Thus a key question is, how can a light 89 
pulse trigger gene expression and re-entrain circadian rhythms at some times but not at 90 
others? Because the neurones in the SCN display circadian rhythms in gene expression that 91 
are maintained even in constant darkness, one possible answer is that these genes regulate 92 
intrinsic neuronal excitability, with the consequence that the SCN neurons are only fully 93 
responsive to light signals at certain stages of the light-dark cycle. Recent findings indicate 94 
that the neuropeptide vasopressin may have a critical role in this process. Transgenic 95 
vasopressin V1a receptor knockout mice show damped circadian activity rhythms (Li et al., 96 
2009), and, interestingly, such mice are resistant to ‘jet lag’. In these mice, light pulses 97 
immediately re-entrain circadian rhythms (Yamaguchi et al., 2013). 98 
Vasopressin is involved in diverse physiological and behavioural processes; 99 
vasopressin secreted from the pituitary gland is essential for fluid and electrolyte balance, 100 
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while vasopressin released within the brain has many other roles, including in social 101 
behaviour, aggression, and in behavioural rhythms (Bielsky et al., 2005; Ludwig & Leng, 102 
2006; Donaldson & Young, 2008; Mieda et al., 2015). Vasopressin is expressed in the 103 
dorsomedial SCN, and is an important output; its secretion into the cerebrospinal fluid (CSF) 104 
peaks in the early morning and declines by late afternoon (Kalsbeek et al., 2010). The targets 105 
for vasopressin released from the SCN include vasopressin cells in other parts of the 106 
hypothalamus, including those in the supraoptic and paraventricular nuclei that regulate 107 
diverse physiological processes including water intake (Gizowski et al., 2016) and 108 
behaviours (Trudel & Bourque, 2010).  109 
The vasopressin cells in the dorsomedial SCN are not direct recipients of retinal 110 
signals; most of the projections from the retina innervate the ventrolateral SCN, which 111 
contains other neuropeptides, including vasoactive intestinal peptide and gastrin-releasing 112 
peptide (Antle et al., 2009). Here we show that neurons in the ventrolateral SCN are densely 113 
innervated by vasopressin-expressing retinal ganglion cells (VP-RGCs), and that more 114 
vasopressin is released in response to light at the end of subjective night than at the end of 115 
subjective day. Thus neurons in the ventrolateral SCN both control the output of vasopressin 116 
from the SCN by their innervation of vasopressin cells in the dorsomedial SCN, and are 117 
themselves regulated by vasopressin inputs from the retina. 118 
 119 
Material & Methods 120 
Ethical Approval 121 
Procedures conducted in the UK were approved by the local Ethics Committee and 122 
the UK Home Office under the Animals Scientific Procedures Act 1986. Experiments in 123 
Germany were approved by the Committee on Animal Health and Care of the local 124 
governmental body and performed in strict compliance with the EEC recommendations for 125 
the care and the use of laboratory animals (86/609/CEE). Experiments in the USA were 126 
performed according to institutional guidelines and approval by the Animal Care and Use 127 
Committees of the Georgia Regents University.  128 
 129 
Animals  130 
Experiments were performed on adult male and female wild-type Sprague-Dawley 131 
and transgenic rats (250-350g), housed under controlled conditions (12h light: 12h dark, 132 
21oC) with free access to food and water. Most of the immunohistochemistry was carried out 133 
on a homozygous line of transgenic rats expressing a vasopressin-eGFP (enhanced green 134 
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fluorescent protein) fusion gene (Ueta et al., 2005).  135 
 136 
PCR 137 
22-week old female wild-type rats were used to collect supraoptic nucleus and retina 138 
tissue. Total RNA was isolated using TRIzol Reagent (Life Technologies, Carlsbad, CA 139 
USA). cDNA was synthesised from 1.5μg of total RNA using the Transcriptor High Fidelity 140 
cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim Germany) according to the 141 
manufacturer’s protocol. The PCR was carried out in a 25-μl reaction volume using Go Taq 142 
G2 Green Master Mix (Promega Corporation, Madison, WI, USA) and 5, 1, or 0.1μl of 143 
cDNA solution were used in each reaction mixture. PCR was performed on a Gene Amp PCR 144 
System 9700 (Life Technologies, Carlsbad, CA USA) using the following conditions: 1 cycle 145 
of 94°C for 30s followed by 30 cycles of 94°C for 30s, 56°C for 45s and 72°C for 1min, with 146 
a final extension step at 72°C for 7min. PCR products are loaded on the 2 % agarose gel and 147 
stained with SYBR Safe DNA Gel Stain (Life Technologies, Carlsbad, CA USA). The primer 148 
sequences have been published previously (Dijk et al., 2004; Gainer et al., 2011). 149 
 150 
Tissue collection and processing 151 
Rats were terminally anesthetized and perfusion-fixed with 4% paraformaldehyde 152 
(PFA) following a heparinized saline flush, post-fixed and cryoprotected as previously 153 
described (Tobin et al., 2010). The eyes were enucleated and placed in 0.1M PB during the 154 
heparinized saline flush before transcardial perfusion with PFA. The cornea was cut around 155 
the outer edge of the iris to remove the lens and vitreous humour and the eyecups were either 156 
placed in 4% PFA solution for 5 min then the retina gently removed and placed back in 4% 157 
PFA for 20min or each eyecup was left in 4% PFA solution for 2h. Some retinas were fixed 158 
in a solution of 4% PFA + 1% glutaraldehyde but otherwise processed as described above. 159 
Tissue was then stored at 4oC in 10% sucrose, then placed in 20% sucrose solution for 160 
120min and finally in 30% sucrose for 12 to 48h, until the tissues had sunk to the bottom of 161 
the vials. In eyes which were required for coronal or transverse sections, the tissues were then 162 
placed in Tissue-Tek CRYO-OCT (optimal cutting temperature compound) embedding 163 
matrix (Fisher Scientific UK)-filled cryo-molds (Sakura Finetek UK Ltd) and gently 164 
manipulated to open up and be in the appropriate orientation and then snap-frozen on 165 
powdered dry ice. The retinas or eyecups were stored at -20oC until 16-µm sections were cut 166 
at -15oC on a cryostat. These sections were thaw-mounted onto SupraFrost slides, allowed to 167 
air-dry for 10min before being stored at -20oC until they were processed for fluorescence 168 
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immunocytochemistry. For retinal flat mounts, 3-4 incisions were made from the perimeter of 169 
the retina almost to the centre to allow the retina to be gently flattened. The flat-mounts were 170 
stored in 0.1M PB until used for immunohistochemistry. After transcardial perfusion, the 171 
brains were removed and placed in a 2% PFA and 15% sucrose solution overnight and 172 
transferred to 30% sucrose until the tissue had sunk. Coronal 40µm sections were cut using a 173 
freezing microtome. 174 
 175 
Immunohistochemistry  176 
For brain sections and rat retina flat mounts, immunohistochemistry was conducted 177 
using a free-floating technique. For retina sections, immunohistochemistry was conducted on 178 
the slides either in slide-mailers (Fisher Scientific UK) or after the sections on each slide 179 
were outlined with hydrophobic ink (ImmEdge, Vector Laboratories) and thereafter kept 180 
horizontal in a light-proofed humid chamber. For each of these techniques, the sections were 181 
thoroughly rinsed in 0.1M PB and incubated in 0.1M glycine in 0.1M PB for 30min at room 182 
temperature. For immunohistochemistry involving exposure to a biotinylated secondary and 183 
fluorescently-tagged streptavidin, sections were blocked for endogenous biotin by incubating 184 
them first in 0.01% avidin in 0.1M PB for 30min, washing and then incubating in 0.001% 185 
biotin in 0.1M PB for 30min. After washing, sections were incubated for 60min in a blocking 186 
buffer consisting of 3-5% normal serum (matched to the host of secondary animal) + 1% 187 
bovine serum albumin (BSA) + 0.1% Triton X-100 diluted in 0.1M PB. If the primary 188 
antibody was raised in goat, BSA was not used in either the blocking buffer or in the 189 
antibody-diluting buffer. The sections were incubated with primary antibodies (Tab. 1) 190 
diluted in the blocking buffer. The primary antibodies were applied for 1-5 days at room 191 
temperature for first day and thereafter at 4oC. After washing in 0.1M PB, sections were 192 
incubated for 60min with secondary antibodies and then washed in 0.1M PB. Sections 193 
exposed to biotinylated secondaries were then incubated for 60min with fluorescently-194 
labelled streptavidin conjugate (1:1000). Both secondary antibodies and fluorescently-195 
labelled streptavidin were diluted in 0.1M PB + 0.03% tween. After further washing, sections 196 
were incubated in DAPI (4',6-diamidino-2-phenylindole, 1:33000, Life Technologies Ltd, 197 
UK) for 5min at room temperature, washed and cover-slipped using either a Mowiol 4-88 198 
(Calbiochem, USA) mounting medium, supplemented with 2.5% DABCO (1,4-199 
diazabicyclo[2.2.2]octane, Sigma) or Prolong Gold (Life Technologies Ltd, UK). No 200 
fluorescent labelling was detected when primary antibodies were omitted or when the 201 
primary antibodies (Tab. 2) were incubated with a five-fold (w/v) of control immunogen 202 
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before being exposed to the tissue sections (the latter control was conducted whenever a 203 
control peptide was available from the supplier of that primary antibody). Most antibody 204 
suppliers provided western blot analysis showing the antibody detecting protein in a single 205 
band of appropriate size.  206 
 207 
Microscopy  208 
Fluorescence signals were acquired either using a Nikon AIR confocal or a Zeiss 209 
LSM510 Axiovert confocal laser scanning microscope. In either case, the images were 210 
acquired at 1024x1024 pixels, using a Nikon Plan Apochromat 1.4 NA x60 oil immersion 211 
objective or a Zeiss Plan NeoFLUAR 1.4 NA x63 oil-immersion objective respectively. In all 212 
cases, emissions for each fluorophore were obtained consecutively to avoid channel cross-213 
talk. Those images taken throughout each cell at Nyquist sampling rates were deconvolved 214 
using Huygens software (Scientific Volume Imaging, Hilversum, Netherlands) and all images 215 
were analysed using NIH ImageJ software (v1.48) and figures constructed using Microsoft 216 
PowerPoint.  217 
 218 
Cloning of rAAV vectors and virus production 219 
In addition to tissue from transgenic rats, for morphological studies we used tissue 220 
from wild-type rats given bilateral intravitreal injections (under isoflurane anesthesia) of a 221 
recombinant adeno-associated virus (rAVV) which caused the expression of Venus or 222 
tdTomato under the control of the vasopressin promoter. The conserved promoter region of 223 
vasopressin gene, chosen using the software BLAT from UCSC (http://genome.ucsc.edu/cgi-224 
bin/hgBlat) was sub-cloned into a rAAV2 backbone carrying an ampicillin-resistance. It 225 
comprises a 1.9kb sequence stretch (revealed by BLAT) that allows for cell-specific 226 
expression in hypothalamic vasopressin neurons. Venus or tdTomato was introduced to the 227 
plasmid as the gene of interest. Production of chimeric virions (recombinant Adeno-228 
associated virus 1/2; rAAV 1/2) was described previously (Knobloch et al., 2012). Briefly, 229 
human embryonic kidney cells 293 (AAV293; Agilent #240073) were calcium phosphate-230 
transfected with the recombinant AAV2 plasmid and a 3-helper system (During et al., 2003). 231 
rAAV genomic titers were determined with QuickTiter AAV Quantitation Kit (Cell Biolabs, 232 
Inc., San Diego, California, USA) and are ~1013 genomic copies per ml.  233 
Rats were anesthetized by medetomidine/ketamine injection and placed in a tiltable 234 
stereotaxic frame. A few drops of phenylephrine chlorhydrate and tropicamide (Mydrin-P®) 235 
to induce mydriasis, oxybuprocaine chlorhydrate (Benoxil® 0.4%) for additional local 236 
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anaesthesia, and ofroxacin (Tarivid® 0.3%) antibiotic was administered into each eye. The 237 
head was tilted with its left or right eye uppermost. Intravitreal injections were performed as 238 
described by Chiu and colleagues (Chiu et al., 2007). Using a very fine needle (33G, 239 
Heraeus, Kulzer Japan Co., Ltd.) attached to a 0.025-ml Hamilton syringe (microliter TM 240 
702), a small puncture was made in the region of the limbus and the needle was lowered into 241 
the vitreous using a micromanipulator. 2-5μl of (rAAV) was intravitreally injected into both 242 
eyes of transgenic or wild-type rats. The needle was left in position for 30-60s and then 243 
withdrawn slowly. The procedure was repeated on the other side of the same eye before being 244 
repeated on the other eye. Injections were performed under a dissecting microscope to ensure 245 
correct positioning of the needle and to monitor loss of fluid from the eye. Intravitreal 246 
injections were performed by a trained ophthalmologist. Virally-transfected rats were left for 247 
two weeks before transcardial perfusion. 248 
 249 
Retrograde Tracing  250 
In 12 eGFP rats under isoflurane anesthesia, 50-100nl of the retrograde tracer (Red-251 
Retrobeads, Lumafluor Inc, Florida, USA, or Fluorogold Sigma) was microinjected 252 
stereotaxically in the left SCN (bregma -1.1, lateral +0.3, depth 8.6mm from dura), IGL 253 
(bregma -4.5, lateral +4.0, depth 5.5mm from dura), OPt (bregma -4.7, lateral 1.3, depth 254 
4.4mm from dura) or bilaterally into the left and right superior colliculus (bregma -5.3mm, 255 
lateral 1.5mm, depth 4.8mm from dura) (Paxinos & Watson, 2006) over 20 min. One week 256 
later, rats were perfused transcardially with 4% PFA and brains and retinas were processed 257 
for immunohistochemistry.  258 
 259 
Fos expression  260 
The effects of light on Fos expression on eGFP-positive RGCs and the SCN was 261 
evaluated in eGFP rats fixed by transcardial perfusion during the day (noon) or night after 262 
light exposure (1000 lux, for 1h, 2h before the end of the night). Standard 263 
immunocytochemistry was performed on floating retinal flat mounts or SCN sections using a 264 
polyclonal antibody raised in rabbit against the N-terminal amino acids 4-17 of the protein 265 
product of human c-fos (PC38, Millipore, UK). For double immunocytochemistry, a 266 
polyclonal antibody raised in chicken against eGFP (Abcam UK) was used. Antibody-antigen 267 
complexes were visualized by using ABC methods with a Vector stain elite kit (Vector 268 
Laboratories, Bucks, UK) intensified with nickel-intensified diaminobenzidine (Ni-DAB; 269 
single immunocytochemistry) or with DAB only (double immunocytochemistry). Fos-270 
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positive nuclei and the percentage of activated cells were counted in the SCN at the level of 271 
maximal cross-sectional area by an observer blind to the treatment group.  272 
 273 
Intracerebroventricular infusion of vasopressin V1a antagonist  274 
Wild-type rats were implanted with a left lateral ventricular brain infusion cannula (Alzet 275 
BIK2, Charles River Ltd, Margate, Kent, UK) under isoflurane anaesthesia via a burr hole in 276 
the skull drilled 0.6mm posterior to and 1.6mm lateral to bregma (Paxinos & Watson, 2006). 277 
The cannula was secured in place using dental cement glued to two stainless steel screws 278 
driven into the skull and then connected via polythene tubing to a subcutaneous osmotic 279 
minipump (Alzet 2001). The pumps were prepared as in instructions and filled with a 280 
vasopressin V1a receptor antagonist (d(CH2)5Tyr(Me)2AVP, Dr. Manning (Kruszynski et al., 281 
1980)) or aCSF and set to deliver at a rate of 416 ng h-1, for 3 days (n=5-7/group). This 282 
antagonist binds similarly to V1a and V1b receptors, and the dose is about twice that used 283 
previously (Subburaju & Aguilera, 2007), who delivered 230 ng h-1 for 28 days and showed 284 
effectiveness at blocking the effects of exogenous vasopressin. Rats were housed singly and, 285 
on the day of experiment, rats were moved into a brightly lit laboratory (1000 lux) and placed 286 
into empty clear cages for 1h. They were then terminally anesthetised for tissue fixation (see 287 
above). 288 
 289 
 290 
In vivo electrophysiology  291 
Urethane-anesthetised adult male wild-type rats (ethyl carbamate 1.25g kg-1, i.p.) 292 
were tracheotomized and the area below the SCN was exposed using a transpharyngeal 293 
approach (Ludwig et al., 2002; Saeb-Parsy & Dyball, 2003). An injection cannula was placed 294 
into the third ventricle (coordinates: 0.6 mm caudal to bregma, 1.5 mm lateral to midline, 5 295 
mm deep) (Paxinos & Watson, 2006) for icv drug administration, and in some experiments a 296 
bipolar stimulating electrode was placed onto the exposed optic nerve, as above, contralateral 297 
to the recording side. Recordings were made from single cells in the SCN using a glass 298 
microelectrode (tip diameter ~1μm) filled with 0.9% NaCl; firing rates were recorded using 299 
Spike2 software and CED 1401 interface (Cambridge Electronic Design, Cambridge, UK) on 300 
a PC. The spontaneous activity of each SCN neuron was recorded for at least 5min before 301 
treatment. Trains of stimuli (matched biphasic pulses; 1-ms pulses, 1mA peak-to-peak; 50Hz 302 
for 0.5s, every 1min) were applied to the contralateral optic nerve. Light was applied at 303 
100lux or 1500lux for 5s at 1-min intervals after the rats were held in dark conditions with 304 
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eyes covered with aluminum foil. Electrical or light stimulation was repeated before, during 305 
and after injection of a vasopressin antagonist into the 3rd ventricle, 2-3mm caudal to the 306 
recording site. The injection cannula was backfilled with vasopressin V1a antagonist (40ng in 307 
2µl aCSF)(Tobin et al., 2010) followed by 2μl of aCSF to prevent diffusion of antagonist into 308 
the SCN; in tests, the first injection of 2μl was thus of aCSF, followed 10min later with an 309 
injection of antagonist. Responses to light were averaged over 10-20 presentations; responses 310 
to antagonist began ~ 5min after injection so the average of responses after this time was 311 
taken. Only one cell was tested in each experiment. One of the cells tested with the antagonist 312 
was not tested with aCSF; in that experiment a different cell had been tested with aCSF with 313 
no response (not shown) but was lost before the antagonist could be injected. 314 
 315 
In vitro electrophysiology 316 
eGFP rats were terminally anesthetized with pentobarbital (50mg kg-1) and retinas 317 
dissected out as described previously (Schmidt & Kofuji, 2011). Retinas were treated with 318 
enzymes by adding collagenase and hyaluronidase (Worthington Chemicals) to Ames' 319 
solution for 10min in a 95% O2/5% CO2 environment, shaken gently before being washed 3 320 
times in carbon-saturated Ames' solution and stored in dark for at least 1h before been moved 321 
to the recording chamber. Retina flat mounts were superfused with Ames’ solution (30°C–322 
32°C) at 3ml min-1. Conventional whole-cell patch-clamp recordings, using a K+-gluconate-323 
based internal solution, were obtained as previously described (Son et al., 2013). Some 324 
neurons were intracellularly labeled with Alexa Fluor 555 (100μM) or biocytin (1%). 325 
Recordings were obtained from eGFP-labeled VP-RGCs neurons. For bath-applied drugs, 326 
mean firing activity and membrane potential values were calculated from a 2-min period 327 
before drug application and in a 2-min period around the peak effect.  328 
 329 
Microdialysis  330 
In wild-type rats, the brain region above the SCN was exposed by the transpharyngeal 331 
approach under urethane anaesthesia (ethyl carbamate 1.25g kg-1, i.p.) as previously 332 
described (Ludwig et al., 2002). An in-house designed U-shaped microdialysis probe 333 
(molecular weight cut-off of 6kDa, Fleaker® hollow fibre, Spectrum Medical Inc., Los 334 
Angeles, CA, USA) was positioned into the left SCN after opening of the meninges. After 335 
implantation, there was an equilibration period of at least 1h before six consecutive 30-min 336 
dialysis samples were collected. The samples were frozen and stored at −20°C until assay for 337 
vasopressin. After two 30-min baseline periods, a stimulating electrode (Clarke 338 
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Electromedical, SNEX-200X) placed onto the optic nerve closely behind the right eye was set 339 
to deliver trains of matched biphasic pulses (0.1ms, 1mA peak-to peak; 50Hz for 5s, every 340 
1min for 30min). In other experiments, light was applied (1min on/1min off for 30min) to the 341 
eye contralateral to the recording site using a portable surgical light (1500lux) at early 342 
morning or late evening during then third sampling period. For the early morning 343 
measurements, rats were anesthetised at ZT0, and kept in the dark (covering the eyes with 344 
aluminum foil) before stimulating with light at ZT4. For the late evening measurements, rats 345 
were anaesthetised at ZT9 and then kept in the dark (covering the eyes with aluminum foil) 346 
before stimulating with light at ZT12. The SCN was dialysed with aCSF (pH 7.2, 347 
composition in mM: NaCl 138, KCl 3.36, NaHCO3 9.52, Na2HPO4 0.49, urea 2.16, CaCl2 348 
1.26, MgCl2 1.18) at 3μl min-1). At the end of each experiment, during sample period six, a 349 
modified aCSF containing 150mM KCl plus 100μM veratridine was retrodialysed into the 350 
SCN to trigger vasopressin release as a control for probe placement, and only data from 351 
experiments in which this evoked at least a 3-fold increase in vasopressin concentration were 352 
analysed. Brains were removed and cut for histological confirmation of microdialysis probe 353 
placement. 354 
Vasopressin in microdialysates was measured after lyophilization as previously 355 
described (Landgraf et al., 1995; Paiva et al., 2016) by a sensitive and selective 356 
radioimmunoassay (RIA; detection limit: 0.1pg sample-1; cross-reactivity less than 0.7%, 357 
RIAgnosis, Sinzing, Germany). Samples for measurement were blind coded.  358 
 359 
Statistics  360 
Fos expression in the retina. Three groups were compared by the non-parametric Kruskall-361 
Wallis test, followed by Mann-Whitney U tests to test the hypotheses a) that light activates 362 
Fos expression in VP-RGCs and b) that expression is higher in the light than in the dark 363 
period.  364 
Retinal vasopressin content. Two groups (n=7) were compared to test the hypothesis that the 365 
vasopressin content of the retina differs between dark and night. Values were compared by a 366 
two-tailed t-test.  367 
Fos expression in the SCN. First, we compared light-induced Fos expression in early vs late 368 
night. In subsequent experiments we tested the hypothesis that a V1a antagonist would 369 
attenuate light-induced Fos expression in the late night. Fos-positive nuclei were counted in 370 
each SCN in 3-5 sections per rat, and the median calculated; to combine these for group 371 
values, the medians were log-transformed as their distributions were skewed; n values are 372 
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animal means. Groups were compared with a one-tailed t-test, as this experiment tested a 373 
predetermined unidirectional hypothesis. 374 
Microdialysis. In the experiment shown in Fig. 6, the basal levels of vasopressin varied in a 375 
3-fold range between experiments, and so all data were normalized to the concentration in the 376 
first basal sample. The normalized data (excluding the first basal sample) from the two 377 
groups were compared by a repeated measures ANOVA followed by pairwise tests, using 378 
Bonferroni’s and Tukey’s multiple comparisons test. 379 
In vivo electrophysiology. Two hypotheses were tested in separate experiments: that V1a 380 
antagonist attenuates SCN responses to light, and that it attenuates SCN responses to 381 
electrical stimulation of the optic nerve. Each of these was tested by a paired comparison of 382 
the (mean) response in control condition and the mean response after application of the 383 
antagonist, using a two-tailed Wilcoxon signed rank test. 384 
 385 
 386 
Results 387 
Characterisation of VP-RGCs 388 
Vasopressin content in the retina has been previously described, and vasopressin has been 389 
found (by immunocytochemistry) to be expressed in some cells in both the ganglion cell layer 390 
and the inner nuclear layer of the retina (Gauquelin et al., 1983; Djeridane, 1994; Moritoh et 391 
al., 2011). We studied these cells in a transgenic rat strain in which eGFP (enhanced green 392 
fluorescent protein) is expressed under the control of the vasopressin promoter (Fig. 1A,B) 393 
(Ueta et al., 2005). eGFP-expressing cells comprised about 1% of cells in the ganglion cell 394 
layer (1.07±0.01% of 33868 cells from 9 retinas), and were sparsely distributed across the 395 
whole retina. By immunocytochemistry, we established that all the eGFP-expressing cells 396 
that we examined in the retina also expressed vasopressin-associated neurophysin: this large 397 
peptide is part of the vasopressin precursor peptide (Fig. 1C). eGFP (and vasopressin 398 
neurophysin) was also expressed in some small cells in the inner nuclear layer, which 399 
contains interneurons that do not project out of the retina.  400 
The VP-RGCs were heterogeneous in size. In the inner nuclear layer, most e-GFP 401 
expressing cells were small: a sample of 21 of these cells had a mean (S.E.M.) cross-sectional 402 
area of 58±2.6µm2 (range 48-85 µm2).  By contrast, in a sample of 43 eGFP-expressing cells 403 
in the ganglion cell layer, 25 small cells had a mean (S.E.M.) cross-sectional area of 404 
83±2.7µm2 (range 62-99µm2), while the ten largest cells had a mean (S.E.M.) cross-sectional 405 
area of 291±13.2µm2 (range 154-333µm2). Using triple immunohistochemistry, we found 406 
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that many large (but not small) VP-RGCs co-expressed the vesicle glutamate transporter 2 407 
(vGLUT-2), indicating that these cells use glutamate as a neurotransmitter (Fig. 1E) 408 
(Fujiyama et al., 2003). In mammals, melanopsin is found in intrinsically photosensitive 409 
RGCs that project to the SCN and plays a critical role in regulating circadian rhythms 410 
(Provencio et al., 2000; Hattar et al., 2002; Hankins et al., 2008). VP-RGCs were often 411 
closely juxtaposed to immunoreactive melanopsin cells (Fig. 1F). Of the small VP-RGCs, 412 
only one cell of 300 counted contained detectable immunoreactive melanopsin, but, of the 413 
large VP-RGCs, 25% (21/80) co-expressed melanopsin. We found no co-localisation of 414 
eGFP with calretinin, parvalbumin, tyrosine hydroxylase, glycine, choline acetyltransferase 415 
or GAD65/67 (Fig. 2A-F), which label known subpopulations of retinal interneurons (Marc 416 
& Jones, 2002).  417 
The vasopressin-eGFP transgene encodes a modified vasopressin precursor with 418 
eGFP fused in-frame at the C terminus (Ueta et al., 2005 and D. Murphy, personal 419 
communication). The signal peptide, vasopressin and neurophysin portions of the precursor 420 
are intact, and may be expressed from the transgene, thus the vasopressin-associated 421 
neurophysin in eGFP rats may reflect either endogenous expression or transgene-driven 422 
expression. We therefore confirmed the expression of vasopressin in retinal cells in wild-type 423 
rats using antibodies against vasopressin-neurophysin (see below), the presence of 424 
vasopressin mRNA in the retina by PCR (Fig. 1D, 3B), and the production of vasopressin by 425 
radioimmunoassay. The vasopressin content of the retina in wild-type rats was higher in the 426 
late afternoon (ZT11) than in the early morning (ZT1; 25±2.6 vs. 52±8pg per retina, n=7 per 427 
group, P<0.015), consistent with light-induced activation of synthesis.  428 
 429 
Venus labelling 430 
 To visualise the axons of the VP-RGCs in wild-type rats, we made intravitreal 431 
injections of a recombinant adeno-associated virus (rAAV) that results in the expression of a 432 
fluorescent protein Venus (Figs. 3A,B; supplementary animation) or tdTomato under the 433 
control of 1.9 kbp of the vasopressin promoter (Fig. 4). We confirmed the successful 434 
transfection of retinal vasopressin cells by immunohistochemistry (Fig. 3B) for vasopressin 435 
neurophysin. This confirms that the large RCGs do indeed express the endogenous 436 
vasopressin gene, as the AAV vector does not contain vasopressin coding sequences. 437 
Unlike the eGFP-vasopressin transgenic rats, where the eGFP is packaged inside the 438 
same vesicles as vasopressin (Ueta et al., 2005), these fluorescent proteins are released into 439 
(and fill) the cytoplasm of the neurons allowing tracking of thin neurites (Knobloch et al., 440 
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2012). In the transfected retinas, we found Venus labelling in the ganglion cell layer but not 441 
in the inner nuclear layer (Fig. 3C,D). Only larger VP-RGCs expressed Venus; no Venus was 442 
found in the small cells in either the inner nuclear layer or the ganglion cell layer. In three 443 
retinas we sampled 220 Venus-labelled cells and 113 melanopsin-labelled cells; 45% of the 444 
Venus-labelled cells contained immunoreactive melanopsin and 88% of the melanopsin cells 445 
contained Venus, suggesting that most melanopsin-containing cells express vasopressin. We 446 
traced the passage of Venus-labelled axons into the optic nerve (Fig. 3E), and found a dense 447 
plexus in the ventrolateral SCN (Fig. 3F). Using triple immunohistochemistry for Venus, 448 
vGLUT-2 and vasoactive intestinal polypeptide (VIP) or gastrin-releasing peptide (GRP) we 449 
found that 74% of VIP cells and 66% of GRP cells were apposed by boutons from Venus-450 
labelled fibres (Fig. 3I,J). The Venus-labelled fibres co-expressed vGLUT-2 indicating that 451 
they were glutamatergic; as expected, vGLUT-2 was not co-expressed with either VIP or 452 
GRP, which are both known to use GABA as a conventional neurotransmitter (Belenky et al., 453 
2008). 454 
We also found Venus-labelled fibres in the intergeniculate leaflet (IGL), which is 455 
involved in regulation of circadian rhythms via its projections to the SCN (Hattar et al., 456 
2006), and in the olivary pretectal nucleus (OPt), which controls the pupillary light reflex 457 
(Gamlin, 2006). However, we found no Venus-labelled fibres entering the superior colliculus, 458 
which is a major projection area of classical image-forming RGCs (Feinberg & Meister, 459 
2015) (Fig. 4), some were found on the outskirts of the superior colliculus, but none were 460 
seen to enter this region. In two animals we transfected the right eye with AAV expressing 461 
Venus and the left eye with an AAV expressing tdTomato, both under the control of the 462 
vasopressin promoter. The labeled fibers terminated in the SCN, IGL and OPt (Fig. 4); most 463 
fibers were found at sites contralateral to the injected eye, but there was a substantial 464 
ipsilateral projection to the SCN in particular.  465 
 466 
Retrograde tracing 467 
We confirmed these projections by retrograde tracing studies (Fig. 3G,H). When 468 
retrograde tracer beads were injected into the SCN, IGL or OPt (n=2-4 per area) we found 469 
labelling of large (but not small) eGFP-positive cells in the ganglion cell layer, and no 470 
labelling of any cells in the inner nuclear layer. We found no labelling after injections into the 471 
superior colliculus (Fig. 3H). To estimate how many of the RGCs that project to the SCN 472 
express vasopressin, we injected fluorogold into the SCN to fill this region completely (Fig. 473 
3G). For the injection which achieved the best fill, we studied seven retinal sections with 474 
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confocal microscopy. Of 176 melanopsin-labelled cells, 142 were retrogradely labelled with 475 
fluorogold; of these, 41 also expressed eGFP. In the same sections, we found only 8 VP-476 
RGCs that were labeled with fluorogold but which appeared to contain no melanopsin. These 477 
experiments confirmed that most of the retinal cells that project to the SCN contain 478 
immunoreactive melanopsin, and that vasopressin is expressed in a substantial subset of these 479 
cells and also in some cells that project to the SCN which did not apparently contain 480 
detectable amounts of immunoreactive melanopsin. 481 
 482 
Light responsiveness of RGCs 483 
To determine the response of VP-RGCs to light we measured the expression of the 484 
immediate early gene c-fos in the retina by immunocytochemical detection of Fos, the protein 485 
product of c-fos. In response to 1-h light stimulation of dark-adapted retinas (ZT21), there 486 
was a significant increase in Fos expression in VP-RGCs (8.1±1.0% of VP-RGC’s expressed 487 
Fos after light exposure vs. 0.2±0.2% with no light exposure, n=3 and n=6 respectively, 488 
p=0.0019, Fig. 5A,B). Fos expression in VP-RGCs was even higher in retinas taken at ZT6 489 
(13.8±3.8%, n=6), suggesting sustained expression of Fos in VP-RGCs throughout the day.  490 
To characterise the responsiveness of VP-RGCs to light, we made in vitro patch-491 
clamp recordings from 88 large RGCs identified by their expression of e-GFP; 58 of these 492 
cells were transiently excited by light, and the other 30 were inhibited (Fig. 5C,D); 493 
previously, all immunoreactive melanopsin RGCs have been reported to be excited by light 494 
(Schmidt et al., 2011). Current-clamp and voltage-clamp recordings from the light-activated 495 
VP-RGCs showed that afferent synaptic activity was increased during light stimulation, 496 
suggesting that activation was mediated at least partially by synaptic input (Fig. 5F). The 497 
close juxtaposition of the VP-RGCs to melanopsin cells indicates that they may receive these 498 
excitatory synaptic inputs from neighboring, intrinsically photosensitive melanopsin cells 499 
(Schmidt et al., 2011; Hughes et al., 2016).  500 
 501 
Vasopressin actions in the SCN 502 
We then recorded the spike activity of single SCN neurons in urethane-anesthetised 503 
rats (Tsuji et al., 2016). About two thirds of light-responsive cells (150/222) were excited by 504 
light (5-s pulses) and about one third were inhibited. In ten cells excited by light (each from a 505 
different rat), responses were measured before and after injection of aCSF and after injection 506 
of a vasopressin V1a receptor antagonist into the third ventricle. The light-induced activation 507 
was unaffected by aCSF injection but was reduced by 30±8% after antagonist injection 508 
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(Wilcoxon matched pairs signed rank test; P=0.004; Fig. 6F). We also tested the responses of 509 
SCN neurons to electrical stimulation of the retino-hypothalamic tract (RHT; 5-s trains at 510 
50Hz) (Fig. 6A-E). Seven SCN neurons (from seven rats) showed a prolonged excitatory 511 
response (for 3-7s after stimulation) that was attenuated by icv injection of the V1a antagonist 512 
(Fig. 6E). 513 
A short light pulse, given during the subjective night, induces Fos expression in the 514 
SCN, and this correlates with the ability of light to phase-shift activity-rest cycles (Fig. 7) 515 
(Ding et al., 1994). Consistent with previous studies, 60-min of light exposure at Z21 induced 516 
robust Fos expression in the SCN, and this activation was significantly greater than that 517 
induced by the same light exposure given at ZT15 (Fig. 7B). In separate experiments, rats 518 
were chronically infused icv with the V1a antagonist or vehicle via a sub-cutaneously 519 
implanted osmotic minipump connected to a cannula implanted in the lateral cerebral 520 
ventricle. Light-induced Fos expression at Z21 was significantly less in rats infused with the 521 
V1a antagonist (Fig. 7A,C) than in vehicle-infused rats. 522 
Finally, we measured vasopressin release in the SCN (by microdialysis in urethane-523 
anaesthetised rats) in response to light exposure. In pilot experiments we found that 524 
application of light (1 min on, 1 min off for 40 min) to the contralateral eye at ZT6 increased 525 
vasopressin release in the SCN from 0.54±0.14 to 1.76±0.35 pg sample-1 in samples collected 526 
every 40 min (n=6 per group, p<0.05). In two further groups of rats, we collected 30-min 527 
samples at the beginning and end of subjective day in before and after light was given for 30 528 
min. The ‘early morning’ group was exposed to light at ZT3 after being maintained in the 529 
dark continuously after the preceding dark phase; the ‘evening’ group was exposed to light at 530 
ZT12 after being maintained in the dark from ZT9, to ensure dark adaptation of light 531 
responsiveness.  In the ‘early morning’ group, light exposure was followed by a significant 532 
increase in vasopressin concentration, whereas in the ‘late evening’ group, light exposure 533 
produced a significant decrease (Fig. 7D). 534 
 535 
Discussion 536 
The present study shows that vasopressin, well known to be an important output of 537 
the SCN (Kalsbeek et al., 2010), is also a time-dependent mediator of light information from 538 
the retina to the SCN, and so is likely to contribute to the effects of vasopressin on jet-lag 539 
(Yamaguchi et al., 2013). The expression of neuropeptides in this projection has clear 540 
functional significance. These cells use glutamate as a neurotransmitter, secreted from small 541 
synaptic vesicles. Because glutamate can be rapidly recycled, this signalling is constantly 542 
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available. However, many of the RGCs that project to the SCN also contain the neuropeptide 543 
PACAP (Hattar et al., 2002; Schmidt et al., 2011), or as described here, vasopressin. At 544 
present, we do not know whether vasopressin and PACAP are co-expressed or are in separate 545 
populations of RGCs. Neuropeptides are not contained in the same vesicles as glutamate, but 546 
are packaged in separate, large vesicles that are synthesised at the cell body and transported 547 
along the axons (Burbach et al., 2001): these vesicles cannot be recycled as small synaptic 548 
vesicles are. Light stimulation rapidly induces Fos expression in VP-RGCs, and induction of 549 
Fos expression is implicated in the regulation of neuronal vasopressin synthesis (Cunningham 550 
et al., 2004). Thus, it is likely that, in VP-RGCs, Fos expression is linked to up-regulation of 551 
peptide synthesis to replenish what has been released from the terminals. However, the path 552 
length from retina to SCN in the rat is >20mm, and (in magnocellular vasopressin neurons) 553 
vasopressin-containing vesicles are transported along axons at only ~140mm/day (Burbach et 554 
al., 2001). Given this, and given the delays between stimulation and production of new 555 
vesicles, the depletion of peptide by light-induced activation of release in the SCN cannot be 556 
replenished without a lag time of several hours. Thus, at the terminals in the SCN, the 557 
availability of peptide for release must be subject to a diurnal cycle of depletion and 558 
replenishment.  559 
We have shown here that light given at the end of the dark phase consistently evokes 560 
measurable vasopressin release in the SCN, whereas light given at the beginning of the dark 561 
phase does not. We predicted that light stimulation would increase vasopressin release from 562 
retinal afferents, and would excite a majority of the first order recipient neurons in the SCN.  563 
The retinal afferents do innervate predominantly VIP and GRP neurons, but not directly 564 
innervate the intrinsic vasopressin cells of the SCN, which are regulated by inhibitory 565 
GABAergic projections by the retinal recipient neurons. However, some of the retinal 566 
recipient neurons are inhibited by light, so there may be activation of intrinsic vasopressin 567 
cells from these inputs. In addition, it has been suggested that GABA may excite some SCN 568 
vasopressin neurons (Belenky et al., 2010). Thus, how much of the vasopressin collected in 569 
the microdialysates is released from the retina projection or released from the endogenous 570 
population of SCN vasopressin neurons in response to light stimulation is unclear. SCN 571 
vasopressin neurons project to the paraventricular nucleus of the hypothalamus, the 572 
subparaventricular zone, medial preoptic area, and into the contralateral SCN. SCN 573 
vasopressin neurons have also axon collaterals which remain inside the boundaries of the 574 
SCN (Pennartz et al., 1998) and release vasopressin from their somata and dendrites (Castel 575 
et al., 1996). 576 
 18
We have also shown that light-induced Fos expression in the SCN is higher at the end 577 
of the night than earlier, and SCN Fos expression has been linked to light-induced phase 578 
shifts. Accordingly, cyclical availability of neuropeptides for release may explain why a light 579 
pulse given close to the end of the night is more likely to result in a phase advance of 580 
circadian rhythms than one given earlier.  581 
Exactly why light is so ineffective at eliciting Fos expression in the early part of the 582 
dark phase remains intriguing; even if the retinal terminals are depleted of vasopressin they 583 
should still be releasing glutamate in response to light. The answer may simply be that, 584 
although c-fos is often thought of as an indiscriminate marker of neuronal excitation, this is 585 
over-simplistic: in magnocellular oxytocin neurons for example, the neuropeptide a-MSH 586 
induces Fos expression but inhibits neuronal activity (Sabatier et al., 2003), while antidromic 587 
stimulation of increased spike activity is completely ineffective at increasing Fos expression 588 
(Luckman et al., 1994). The likely mechanistic link between synaptic activation appears to be 589 
via increased intracellular calcium, and as vasopressin is a potent mobiliser of intracellular 590 
calcium stores (Sabatier et al., 1998), it may be a particularly potent inducer of Fos 591 
expression.  592 
Vasopressin is involved in diverse physiological and behavioural processes; 593 
vasopressin secreted from the pituitary gland is essential for fluid and electrolyte balance, but 594 
vasopressin released within the brain has many roles, including in social behaviour, 595 
aggression, and in behavioural rhythms. Vasopressin is an important output of the SCN; its 596 
secretion into the CSF peaks in the early morning and declines by late afternoon (Kalsbeek et 597 
al., 2010), and its targets include vasopressin cells in other parts of the hypothalamus. In 598 
particular, vasopressin released from the SCN during late sleep activates osmosensory 599 
afferents to the vasopressin neurons in the supraoptic nucleus (Trudel & Bourque, 2010) and 600 
to neurons in the organum vasculosum of the lamina terminalis (Gizowski et al., 2016). 601 
Supraoptic neurons secrete vasopressin from nerve terminals in the posterior pituitary which 602 
acts on the kidneys to concentrate the urine. Regulation of this antidiuretic system by the 603 
SCN suppresses nocturnal enuresis, and is important in maintaining sleep. Magnocellular 604 
vasopressin neurones of the supraoptic nucleus also directly control a diversity of behavioural 605 
processes, via central axonal projections and via extensive dendritic secretion of vasopressin 606 
(Ludwig & Leng, 2006; Neumann & Landgraf, 2012; Stoop, 2012). Thus although 607 
vasopressin is expressed at several sites in the nervous system as well as in the retina, it 608 
appears that some of these vasopressin neurons are linked in functionally coherent chains to 609 
integrate multiple physiological and behavioural functions. 610 
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Shift work that includes a night-time rotation and long distance travel has become an 611 
unavoidable attribute of today's 24-h society. The related disruption of the human circadian 612 
time organization leads in the short-term to an array of jet-lag-like symptoms, and in the 613 
long-run it contributes to weight gain and obesity, metabolic syndrome, type II diabetes, and 614 
cardiovascular disease. Studies suggest increased cancer risk, symptoms of insomnia, 615 
depression, elevated cortisol levels, cognitive impairment, and premature mortality (Hastings 616 
et al., 2003; Froy, 2011; Kondratova & Kondratov, 2012). The mechanisms leading to 617 
circadian dysfunction are largely unknown. The reported association of vasopressin with jet-618 
lag (Yamaguchi et al., 2013) raises the interesting possibility that interventions in vasopressin 619 
signalling from the retina may have important therapeutic benefits. 620 
 621 
 622 
 623 
Figure Legends 624 
Figure 1: Vasopressin neurons in the retina.  625 
A, Flat mount of retina, focused on the ganglion cell layer (GCL), shows dispersed eGFP-expressing 626 
cells (green cells); the blue staining is a nuclear marker DAPI, to show the location of all cells in the 627 
field of view; the inset shows the location of the image within the flat mount. B, eGFP-cells occur in 628 
both the ganglion cell layer (GCL) and the inner nuclear layer (INL), as shown in a cross section of 629 
the flat mount. C, eGFP-cells express vasopressin-neurophysin (VP-NP); the successive images show 630 
fluorescence for eGFP, immunoreactive VP-NP, and overlaid images. D, PCR confirmation of 631 
expression of vasopressin mRNA (VP, 77bp) and actin mRNA in the supraoptic nucleus (positive 632 
control) and the retina of wild type rats; the supraoptic nucleus contains magnocellular neurons that 633 
project to the posterior pituitary gland. Note there is no detectable oxytocin mRNA (OXT, 62bp) in 634 
the retina; oxytocin is a closely related peptide that is also expressed in the supraoptic nucleus. E, 635 
eGFP-cells (shown in a flat mount) co-express the vesicle glutamate transporter vGLUT-2 (white 636 
arrows) indicating that they use glutamate as a conventional neurotransmitter. F, Some eGFP-cells co-637 
express the photopigment melanopsin (white arrows, yellow arrow shows a cell immunopositive for 638 
melanopsin only). 639 
 640 
Figure 2: Vasopressin neurons in the retina. 641 
Immunohistochemistry for retinal cell types Fluorescence immunohistochemistry showing that eGFP-642 
expressing RGCs (green in top layer) and amacrine cells (green lower layer) do not co-express 643 
markers commonly used to identify retinal cells (red), including calcium binding proteins (A-C), 644 
neuropeptides (D-F), and “classical” transmitters (G-J). 645 
 646 
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Figure 3: VP-RGC transfection and projections.  647 
A, Scheme of the viral vector used to infect VP-RGCs. B, Intravitreal injection in wild type rats of a 648 
rAAV-expressing Venus (green) under the control of the vasopressin promoter infects RGCs that 649 
express vasopressin neurophysin (VP-NP, red; yellow in overlay). C, Venus labelling in a retinal flat 650 
mount. D, dendrites of RGCs branching into the inner nuclear layer (INL) (D) or ganglion cell layer 651 
(GCL) (Di). E, Venus-labelled axonal projections converge on the optic disc, where the optic nerve 652 
leaves the retina. F, enlarged in Fi, The VP-RGCs project (green fibres; Venus) to the ventrolateral 653 
SCN; intrinsic vasopressin cells in red. G,H, Retrograde tracer is found in some VP-RGCs (Gi,Hi) 654 
after microinjection into the SCN (G) (fluorogold), but not after injection into the superior colliculus 655 
(H, Fluoro-Red beads). I,J, Terminal boutons of Venus-labelled fibres in the SCN express vGLUT-2 656 
and target (I) vasoactive intestinal polypeptide (VIP) and (J) gastrin-releasing peptide (GRP) cells. 657 
The blue staining is a nuclear marker DAPI. 3V 3rd ventricle, OC optic chiasm; ITR inverted terminal 658 
repeat sequence. 659 
 660 
Figure 4: Projections of VP-RGCs 661 
DAB immunohistochemistry in wild type rats after intravitreal injection of a rAAV-expressing Venus 662 
under the control of the vasopressin promoter into the retina shows some fibers projecting to the (A) 663 
integeniculate leaflet and (B) olivary pretectal nucleus, but not to the (C) superior colliculus. D, 664 
Scheme of the viral vectors used to infect VP-RGCs. Intravitreal injection of a rAAV-expressing 665 
Venus (green) into (E) the right retina and tdTomato (red) into (F) the left retina shows (G-K) that the 666 
fibers terminate in the SCN, intergeniculate leaflet (IGL) and olivary pretectal nucleus (OPt) with the 667 
majority contralateral to the injected eye. 668 
 669 
Figure 5: Light exposure excites VP-RGCs.  670 
A, The expression of Fos in VP-RGCs in the day (ZT6). B, Expression is higher in the day (ZT6) than 671 
in the dark (ZT21) and is induced by light stimulation in the dark (mean difference 7.5, 95% CI 4.0 to 672 
11.0, **P=0.0019). Patch-clamp recordings of VP-RGCs showing examples of (C) a transient increase 673 
in spike activity during light exposure, and (D) inhibition of spike activity.  E, Example of a patch-674 
clamp recorded eGFP-labeled RGC filled with biocytin (red; overlay with green gives the yellow 675 
signal in the soma). F, spikes in response to light are initiated by excitatory postsynaptic potentials 676 
(arrow). G, Summary of electrophysiology data showing changes in voltage potential (Vm, for 677 
stimulated (mean difference 16.2, 95% CI 12.8 to 19.6, ***P=0.0001) and inhibited neurons (mean 678 
difference -6.56, 95% CI -7.9 to -5.2, ***P=0.0001), n=58 excited cells, 30 inhibited cells, means + 679 
S.E.M; *** P<0,001). 680 
Figure 5B source data; Figure 5G source data 681 
 682 
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Figure 6: Vasopressin effects on SCN cells. 683 
A,B, Icv injection of a vasopressin V1a antagonist blocks the response of an SCN neuron in vivo to 684 
electrical stimulation of the RHT (grey bar), shown in post-stimulus time histograms before (A) and 685 
after (B) antagonist injection. C, Example of the response of a SCN cell to repeated electrical 686 
stimulation of the RHT; the black symbols plot the number of spikes recorded in the 6s after 687 
stimulation of the RHT for 0.5s at 50Hz delivered every minute; the open symbols plot the number of 688 
spikes in the following 6s. A V1a antagonist given icv (arrow) markedly attenuates the response to 689 
stimulation for about 20 min after a lag of 3 min.  D, Mean (S.E.M.) response to RHT stimulation of 690 
the same cell, shown in blue for the first ten responses plotted in C and in red for the ten responses 691 
plotted between 20 and 30 min in C. E, Mean responses to RHT stimulation of 7 SCN cells plotted as 692 
% differences to control firing rate after icv injection of aCSF followed by icv injection of the V1a 693 
antagonist and after recovery (washout) (***P=0.009 vs. control; two-tailed Wilcoxon signed rank 694 
test; numbers in columns are n/group).  F, Icv injection of antagonist attenuates the responses of SCN 695 
neuron in vivo to light: this panel shows the response of a representative SCN neuron to light; it shows 696 
the mean (S.E.M.) responses to repeated light exposures before and after injection of the antagonist 697 
(n=9 in each case). 698 
Figure 6E source data.xlsx; Figure 6F source data.xlsx 699 
 700 
Figure 7: Vasopressin effects on SCN Fos expression. 701 
A, Hypothalamic sections at the level of the SCN stained for Fos (black nuclear stain), and lightly 702 
counterstained with nuclear fast red. A 60-min light pulse presented at the beginning of the dark 703 
period (ZT15) induces more Fos expression in the SCN than a pulse presented towards the end of the 704 
dark period (ZT21). Light-induced Fos expression is attenuated by a vasopressin V1a antagonist. B, 705 
Data (median numbers of Fos cells counted per SCN section) from all individual animals are given as 706 
points (mean difference 0.39, 95%CI 0.1 to 0.68, **P=0.0095). C, Data (median numbers of Fos cells 707 
counted per SCN section) from all individual animals are given as points (mean difference 0.54, 708 
95%CI -1.1 to 0.02, **P=0.029). D, Light stimulation increases the vasopressin content in SCN 709 
microdialysates in the ‘early morning’ group (light exposure at ZT3) but not the ‘evening’ group 710 
(light at ZT12) as measured by radioimmunoassay (RM ANOVA followed by Bonferroni’s and 711 
Tukey’s multiple comparisons tests). Mean difference 0.54, 95%CI 0.23 to 0.85, ***P=0.0001; mean 712 
difference 0.41, 95%CI 0.1 to 0.72, **P=0.005; mean difference -0.47, 95%CI -0.75 to -0.18, 713 
+++P=0.0006. Bars show means+S.E.M. Numbers in columns are n per group.  714 
Figure 7B source data.xlsx; Figure 7C source data.xlsx; Figure 7D source data.xlsx 715 
 716 
Table 1. Primary Antibodies used for retina and SCN immunohistochemistry  717 
 718 
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Table 2. Secondary and visualisation reagents used for retina and SCN  719 
 720 
Supplementary animation: 721 
Animation of confocal images, showing cumulative stacking of sequential z slices from a 722 
retina flat mount, providing a 3D representation of the dendritic arborization of Venus filled 723 
(green) vasopressin expressing retinal ganglion cells. 724 
 725 
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 Table:  
T1: Primary antibodies used for retina and SCN immunohistochemistry 
 
T2: Secondary antibodies and visualization reagents used for retina and SCN 
immunohistochemistry 
 
 
PRIMARY ANTIBODIES CODE SUPPLIER DILUTION HOST 
eGFP AB3080 Millipore, UK 1: 1000 rabbit 
eGFP MAB3580 Millipore, UK 1: 1000 mouse 
Venus (GFP &YFP) ab13970 Abcam, UK 1:15000 chicken 
tdTomato 362496 Clontech 1:500 rabbit 
Gastrin Releasing Peptide ab43834 Abcam, UK 1:500 rabbit 
Vasoactive  
Intestinal Peptide 
20077 Immunostar,Newmarket 
Scientific, UK 
1:500 rabbit 
Melanopsin AB19306 Abcam, UK 1:100 rabbit 
Neuropeptide Y 22940 Immunostar, Newmarket 
Scientific, UK 
1:500 rabbit 
Somatostatin 20067 Immunostar, Newmarket 
Scientific, UK 
1:500 rabbit 
Vasopressin PS41 Professor H Gainer (NIH, 
Bethesda, MD) 
1:1000 mouse 
Vasopressin PC234L Merck Chemicals Ltd. UK 1:200 rabbit 
Calbindin D-28K 300 Swant, Switzerland 1:500 mouse 
Calretinin 7699/3H Swant, Switzerland 1:500 rabbit 
Parvalbumin 24428 Immunostar,Newmarket 
Scientific, UK 
1:500 rabbit 
Glutamate Decarboxylase 
65/67 
ADI-MSA-
225 
Enzo Life Sciences (UK) 
LTD. Exeter, UK 
1:1000 mouse 
Vesicular Glutamate 
Transporter 2 
135404 Synaptic Systems,  
Germany 
1:1000 guinea pig 
Glycine  AB5020 Millipore, UK 1:100 rabbit 
Tyrosine Hydroxylase AB152 Millipore, UK 1:1000 rabbit 
Dopamine Beta Hyroxylase AB1585 Millipore, UK 1:2000 rabbit 
Choline Acetyltransferase AB144P Millipore, UK 1:1000 goat 
Fos PC38 Millipore, UK 1:20000 rabbit 
Fos 226003 Synaptic Systems, 
Germany 
1:100000 rabbit 
 
 
SECONDARY 
ANTIBODIES: 
CODE SUPPLIER DILUTION Host  
Biotin-anti-rabbit IgG BA-1100 Vector Laboratories Ltd, UK 1:500 horse 
Biotin-anti-mouse IgG BA-2001 Vector Laboratories Ltd, UK 1:500 horse 
Biotin-anti-guinea pig IgG BA-7000 Vector Laboratories Ltd, UK 1:500 goat 
Biotin-anti-rabbit IgG BA-1000 Vector Laboratories Ltd, UK 1:500 goat 
Biotin-anti-mouse IgG BA-9200 Vector Laboratories Ltd, UK 1:500 goat 
Alexa 488 anti-chicken  A11039 Life Technologies, UK 1:500 goat 
Biotin-Anti-Chicken IgY   703-066-155 Stratech Scientific Ltd, UK 1:500 donkey 
 
 
    
 
VISUALISED WITH: 
Streptavidin, Alexa Fluor 
488 conjugate 
S-11223 Life Technologies, UK 1:500  
Streptavidin, Alexa Fluor 
555 conjugate 
S-21381 Life Technologies, UK 1:500  
 
Streptavidin, Alexa Fluor 
647 conjugate 
S-21374 Life Technologies, UK 1:500   
